Dr. Siham Sabri received her PhD from Paris-7 Denis Diderot University in France, followed by Postdoctoral training in France and England before coming to Canada as a Research Associate at the University of Alberta and subsequently an Assistant Professor at McGill.
Research Interests: Her research focuses on understanding the mechanisms of increased growth of tumor vessels (angiogenesis) and tumor infiltration (invasion) in Glioblastoma multiforme (GBM). GBM is the most common malignant primary brain tumor in adults and has a devastating outcome. Despite a multimodal treatment combining surgery, radiation therapy and chemotherapy, the median survival rate of patients diagnosed with GBM is approximately 15 months and only five per cent of patients survive more than 5 years. She has established a large research program with her team and several collaborators to translate findings from the lab to clinical trials and identify biomarkers of response to treatment using a platform of innovative technologies. We will also test new compounds to inhibit tumor angiogenesis and invasion in mice bearing intracranial injections of GBM tumor cells established in my laboratory. This strategy will lead to the implementation of targeted therapies in clinical practice in GBM.
molecular mechanisms regulating tumor angiogenesis and invasion in Glioblastoma (GBM)
relationship between The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) and angiogenesis and invasion in Glioblastoma in orthotopic GBM models and tissue samples from GBM patients
identification and validation of new MGMT-binding partners using a proteomic-based approach
identification of blood-based biomarkers of response to anti-angiogenic agents in GBM
response to radiation therapy in triple negative breast cancer
molecular mechanisms of radiation-induced lung fibrosis